Incidence of and risk factors for visual acuity loss among patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy
- PMID: 16766032
- DOI: 10.1016/j.ophtha.2006.03.021
Incidence of and risk factors for visual acuity loss among patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy
Abstract
Purpose: To describe the incidence of and risk factors for visual acuity loss among patients with AIDS and cytomegalovirus (CMV) retinitis in the era of highly active antiretroviral therapy (HAART).
Design: Multicenter prospective observational study.
Participants: Three hundred seventy-nine patients with AIDS and CMV retinitis (494 eyes).
Methods: Follow-up every 3 months with medical history, ophthalmologic examination, and laboratory testing.
Main outcome measures: Incidence of visual acuity loss to 20/50 or worse, to 20/200 or worse, and of doubling of the visual angle in eyes affected with CMV retinitis.
Results: Among the 494 eyes with CMV retinitis, the baseline frequencies of visual acuity loss to 20/50 or worse and to 20/200 or worse were 29% and 15%, respectively. Over a median follow-up period of 3.1 years, the incidences of visual acuity loss to 20/50 or worse, to 20/200 or worse, and of doubling of the visual angle were 0.10/eye-year (EY), 0.06/EY, and 0.13/EY, respectively. Immune recovery was associated with a 42% reduction in vision loss to 20/50 or worse and with a 61% reduction in vision loss to 20/200 or worse after adjusting for confounding. Of the patients with immune recovery at baseline, 17% had immune recovery uveitis (IRU). In these patients, the incidence rate of 20/50 or worse vision was similar to that observed in patients without immune recovery (0.17/EY vs. 0.16/EY), but the incidence of 20/200 or worse vision was similar to that observed among patients with immune recovery (0.04/EY vs. 0.04/EY).
Conclusions: Cytomegalovirus retinitis is associated with a substantial risk of incident vision loss in the era of HAART. Those who have HAART-induced immune recovery have approximately 50% lower risk of visual acuity loss. Presence of IRU at baseline attenuated the protective effect of immune recovery for moderate vision loss but not for blindness.
Similar articles
-
Causes of visual acuity loss among patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy.Ophthalmology. 2006 Aug;113(8):1441-5. doi: 10.1016/j.ophtha.2006.03.022. Epub 2006 Jun 15. Ophthalmology. 2006. PMID: 16781775
-
Effect of cytomegalovirus retinitis on the risk of visual acuity loss among patients with AIDS.Ophthalmology. 2007 Mar;114(3):591-8. doi: 10.1016/j.ophtha.2006.08.008. Epub 2006 Nov 22. Ophthalmology. 2007. PMID: 17123624
-
Cytomegalovirus retinitis and immune recovery uveitis in AIDS patients treated with highly active antiretroviral therapy in Taiwanese.Ocul Immunol Inflamm. 2008 May-Jun;16(3):83-7. doi: 10.1080/09273940802056307. Ocul Immunol Inflamm. 2008. PMID: 18569793
-
Cytomegalovirus retinitis in the era of highly active antiretroviral therapy.Herpes. 2007 Dec;14(3):66-71. Herpes. 2007. PMID: 18371289 Review.
-
AIDS and ophthalmology: the first quarter century.Am J Ophthalmol. 2008 Mar;145(3):397-408. doi: 10.1016/j.ajo.2007.12.001. Am J Ophthalmol. 2008. PMID: 18282490 Review.
Cited by
-
Long-term Outcomes of Cytomegalovirus Retinitis in the Era of Modern Antiretroviral Therapy: Results from a United States Cohort.Ophthalmology. 2015 Jul;122(7):1452-63. doi: 10.1016/j.ophtha.2015.02.033. Epub 2015 Apr 17. Ophthalmology. 2015. PMID: 25892019 Free PMC article.
-
Visual field loss in patients with cytomegalovirus retinitis.Ophthalmology. 2011 May;118(5):895-901. doi: 10.1016/j.ophtha.2010.09.017. Epub 2010 Dec 13. Ophthalmology. 2011. PMID: 21146225 Free PMC article.
-
Cytomegalovirus retinitis in the highly active anti-retroviral therapy era.Ann Eye Sci. 2022 Mar;7:5. doi: 10.21037/aes-21-18. Ann Eye Sci. 2022. PMID: 35498636 Free PMC article.
-
An All-in-One Highly Multiplexed Diagnostic Assay for Rapid, Sensitive, and Comprehensive Detection of Intraocular Pathogens.Am J Ophthalmol. 2023 Jun;250:82-94. doi: 10.1016/j.ajo.2023.01.021. Epub 2023 Jan 26. Am J Ophthalmol. 2023. PMID: 36709019 Free PMC article.
-
Effect of individualized therapy for AIDS patients with cytomegalovirus retinitis in intravitreal ganciclovir injections.Int J Ophthalmol. 2019 Aug 18;12(8):1351-1355. doi: 10.18240/ijo.2019.08.19. eCollection 2019. Int J Ophthalmol. 2019. PMID: 31456929 Free PMC article.
Publication types
MeSH terms
Grants and funding
- 5M01 RR 00350/RR/NCRR NIH HHS/United States
- 5M01 RR 00865/RR/NCRR NIH HHS/United States
- 5M01 RR 05096/RR/NCRR NIH HHS/United States
- 5M01 RR00043/RR/NCRR NIH HHS/United States
- 5M01 RR00046/RR/NCRR NIH HHS/United States
- 5M01 RR00047/RR/NCRR NIH HHS/United States
- EY 00405/EY/NEI NIH HHS/United States
- U01 AI 27660/AI/NIAID NIH HHS/United States
- U01 AI 27663/AI/NIAID NIH HHS/United States
- U01 AI 27670/AI/NIAID NIH HHS/United States
- U01 AI 27674/AI/NIAID NIH HHS/United States
- U01 AI25868/AI/NIAID NIH HHS/United States
- U01 AI25903/AI/NIAID NIH HHS/United States
- U01 AI32783/AI/NIAID NIH HHS/United States
- U10 EY 08052/EY/NEI NIH HHS/United States
- U10 EY 08057/EY/NEI NIH HHS/United States
- U10 EY 08067/EY/NEI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical